Alternative sampling methods for cervical cancer screening: practical perspectives from the laboratory

Richter, Karin Louise

doi:10.1080/20742835.2013.11441215

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The method and main results of this study have previously been reported. 4,19,20 Based on the wide age range, the estimated HIV prevalence of this group was between 19% and 33%.…”

Section: Settingmentioning

confidence: 99%

HPV L1 capsid protein detection in high-risk human papillomavirus-positive cervical smears

Heunis

Horton

Richter

et al. 2014

Southern African Journal of Gynaecological Oncology

Self Cite

View full text Add to dashboard Cite

HPV L1 capsid protein detection in high-risk human papillomavirus-positive cervical smears IntroductionThe current prevalence of cervical precursor lesions in South Africa is not precisely known, but data from published studies suggest an increase in the incidence of abnormalities diagnosed on cytology. 1-3 Richter er al 4 recently reported abnormal cytology results in 17% of 1 472 women screened in an urban setting in South Africa, a prevalence that is higher than that described in the general population previously. This increase is attributed to a higher prevalence of infection with oncogenic human papillomavirus (HPV), a DNA virus that causes cervical carcinoma.5 HPV types are classified according to oncogenic potential into high-, intermediateand low-risk categories. 6 AbstractBackground: The L1 capsid protein is a viral nuclear protein that encapsidates the human papillomavirus (HPV) DNA to build new infectious particles. Previous studies in immune-competent patients have shown that detectable L1 protein in lowgrade squamous intraepithelial lesion (LSIL) smears is associated with remission in 60-75% of cases. Thus, the test can reduce interventions by approximately 75%.Objective: This study was performed to evaluate the use of HPV L1 capsid protein detection on cytology samples in a population with relatively high human immunodeficiency virus (HIV) prevalence and with known high-risk HPV (hrHPV) DNA results.Setting: Samples were obtained during a cervical cancer screening study at primary healthcare clinics in the Tshwane district, Gauteng. The HIV prevalence of the target group was estimated to be between 20% and 30%. Method:Conventional cervical cytology smears of 575 women were microscopically assessed and diagnosed. In addition, women were tested for the presence of HPV DNA on a cervical or vaginal sample. Immunocytochemical analysis was performed on morphologically abnormal smears and on a 52 control group smears reported to be negative for HPV DNA and morphological abnormalities. The detection of L1 capsid protein was carried out with the Cytoactiv® HPV L1 screening set, an antibody-based immunocytochemical stain.Results: A cytological diagnosis of LSIL was made in 19 women (3.3%), high-grade squamous intraepithelial lesions (HSILs) in 42 (7.5%) and malignancy in 1 (0.2%). Of the LSIL cases, 10 of 19 (52.6%) stained positive for the presence of the L1 protein, while only one of 42 HSIL (2.4%) cases stained positive. Three hundred and four cases (52.9%) tested positive for hrHPV DNA, including women with LSIL, HSIL and malignancy. All of the control cases stained negative for the L1 capsid protein.Conclusion: hrHPV was not a useful triage test for women with abnormal cellular morphology in this population. Promising results were reported for Cytoactiv® immunostaining as a triage test for patients with LSIL, but it added no value to samples known to be HPV-negative or reported to be morphologically negative. The immunostaining of smears reported to be HSIL or worse were almost universally negative, supp...

show abstract

“…The method and main results of this study have previously been reported. 4,19,20 Based on the wide age range, the estimated HIV prevalence of this group was between 19% and 33%.…”

Section: Settingmentioning

confidence: 99%

HPV L1 capsid protein detection in high-risk human papillomavirus-positive cervical smears

Heunis

Horton

Richter

et al. 2014

Southern African Journal of Gynaecological Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the first article in this supplement, Richter investigates alternative screening options, such as patient self-sampling combined with high-risk human papillomavirus (HPV)based testing, which has the potential to increase cervical cancer screening coverage, especially in areas in which screening is inadequate. 1 The article focuses on sample collection, transportation, preparation, testing and the interpretation of the results. As the virologist in charge of the CANSA-funded study, Dr Richter was intimately involved in these aspects and provides a personal perspective.…”

mentioning

confidence: 99%

About this supplement…

Snyman

2013

Southern African Journal of Gynaecological Oncology

View full text Add to dashboard Cite

In 2009, The Cancer Association of South Africa (CANSA) awarded its biggest research grant to date to the HPV Cervical Cancer Research Fund, under the auspices of Prof Greta Dreyer. This grant enabled a group of researchers from different disciplines to conduct a project to investigate large-scale cervical cancer screening of peri-urban women using cytology and molecular testing. The main findings of this study, performed in the Tshwane Health District, are reported in this supplement which is introduced by Dr Carl Albrecht, Head of Research, CANSA.

show abstract

Challenges in preventative care and research in primary healthcare facilities: information obtained during implementation of a cervical cancer screening project in the Tshwane Health District

Dreyer

Mnisi

Maphalala

2013

Southern African Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Alternative sampling methods for cervical cancer screening: practical perspectives from the laboratory

Cited by 3 publications

References 20 publications

HPV L1 capsid protein detection in high-risk human papillomavirus-positive cervical smears

HPV L1 capsid protein detection in high-risk human papillomavirus-positive cervical smears

About this supplement…

Challenges in preventative care and research in primary healthcare facilities: information obtained during implementation of a cervical cancer screening project in the Tshwane Health District

Contact Info

Product

Resources

About